Hsa_circ_0007967 promotes gastric cancer proliferation through the miR-411-5p/MAML3 axis.


Journal

Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035

Informations de publication

Date de publication:
30 Mar 2022
Historique:
received: 30 12 2021
accepted: 17 03 2022
revised: 10 03 2022
entrez: 31 3 2022
pubmed: 1 4 2022
medline: 1 4 2022
Statut: epublish

Résumé

Circular RNAs are an important kind of noncoding RNAs and involved in cancerogenesis, but the specific mechanism between gastric cancer and circRNAs needs further study. Hsa_circ_0007967 was selected by RNA sequencing. Here, hsa_circ_0007967 was highly expressed in gastric cancer tissues than adjacent normal tissues. Overexpressing hsa_circ_0007967 promoted gastric cancer cell proliferation in vitro and in vivo, while suppression of hsa_circ_0007967 inhibited gastric cancer cell proliferation in vitro and in vivo. Mechanistically, hsa_circ_0007967 sponged miR-411-5p to increase MAML3 expression. Overall, hsa_circ_0007967 is a promising biomarker for gastric cancer diagnosis and a potential molecule for gastric cancer treatment.

Identifiants

pubmed: 35354791
doi: 10.1038/s41420-022-00954-1
pii: 10.1038/s41420-022-00954-1
pmc: PMC8969178
doi:

Types de publication

Journal Article

Langues

eng

Pagination

144

Subventions

Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057
Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057
Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057
Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057
Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057
Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057
Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057
Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057
Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057
Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057
Organisme : Government of Jiangsu Province (Jiangsu Province)
ID : Z2019057

Informations de copyright

© 2022. The Author(s).

Références

RNA Biol. 2015;12(4):381-8
pubmed: 25746834
Mol Cell. 2017 Apr 6;66(1):22-37.e9
pubmed: 28344082
Cell Death Differ. 2019 Dec;26(12):2758-2773
pubmed: 31092884
Nucleic Acids Res. 2016 Apr 7;44(6):2846-58
pubmed: 26861625
Cell Death Differ. 2018 Dec;25(12):2195-2208
pubmed: 29795334
World J Gastroenterol. 2014 Feb 21;20(7):1635-49
pubmed: 24587643
Oncogene. 2008 Sep 1;27(38):5138-47
pubmed: 18758483
EBioMedicine. 2018 Aug;34:267-274
pubmed: 30078734
RNA Biol. 2017 Mar 4;14(3):361-369
pubmed: 28080204
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Mol Cell. 2017 Apr 6;66(1):9-21.e7
pubmed: 28344080
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Lett. 2019 Sep 10;459:216-226
pubmed: 31199987
Mol Cell Proteomics. 2016 Feb;15(2):614-23
pubmed: 26598640
Mol Cell. 2013 Sep 26;51(6):792-806
pubmed: 24035497
Nat Struct Mol Biol. 2015 Mar;22(3):256-64
pubmed: 25664725
Cell Death Differ. 2017 Feb;24(2):357-370
pubmed: 27886165
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14542-7
pubmed: 25253891
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326

Auteurs

Quanbin Zha (Q)

Department of Oncology, Jintan Hospital, Jiangsu University, Changzhou, 213200, People's Republic of China.

Xi Wu (X)

Department of Oncology, the First Affifiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.

Jingxin Zhang (J)

Department of General Surgery, the Affifiliated People's Hospital of Jiangsu University, Zhenjiang Clinic School of Nanjing Medical University, Zhenjiang, 212002, People's Republic of China.

Tingting Xu (T)

Department of Oncology, the First Affifiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.

YongKang Shi (Y)

Department of Oncology, Jintan Hospital, Jiangsu University, Changzhou, 213200, People's Republic of China.

Yayun Sun (Y)

Department of Neurology, Jintan Hospital, Jiangsu University, Changzhou, 213200, People's Republic of China.

Yuan Fang (Y)

Department of Oncology, the First Affifiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.

Yunru Gu (Y)

Department of Oncology, the First Affifiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.

Pei Ma (P)

Department of Oncology, Jintan Hospital, Jiangsu University, Changzhou, 213200, People's Republic of China. mapei@njmu.edu.cn.
Department of Oncology, the First Affifiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. mapei@njmu.edu.cn.

Yongqian Shu (Y)

Department of Oncology, Jintan Hospital, Jiangsu University, Changzhou, 213200, People's Republic of China. yongqian_shu@163.com.
Department of Oncology, the First Affifiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. yongqian_shu@163.com.
Department of Oncology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, 210029, People's Republic of China. yongqian_shu@163.com.
Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 210029, People's Republic of China. yongqian_shu@163.com.

Shengwang Tian (S)

Department of Oncology, Jintan Hospital, Jiangsu University, Changzhou, 213200, People's Republic of China. tswjtyy@163.com.

Classifications MeSH